Zami Aberman
2014
In 2014, Zami Aberman earned a total compensation of $1M as Co, CEO at Pluristem Therapeutics, a 38% decrease compared to previous year.
Compensation breakdown
| Salary | $524,200 |
|---|---|
| Stock Awards | $492,000 |
| Other | $19,347 |
| Total | $1,035,547 |
Aberman received $524.2K in salary, accounting for 51% of the total pay in 2014.
Aberman also received $492K in stock awards and $19.3K in other compensation.
Rankings
In 2014, Zami Aberman's compensation ranked 7,449th out of 13,032 executives tracked by ExecPay. In other words, Aberman earned more than 42.8% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 7,449 out of 13,032 | 43rd |
Division Manufacturing | 2,751 out of 4,966 | 45th |
Major group Chemicals And Allied Products | 935 out of 1,686 | 45th |
Industry group Drugs | 736 out of 1,365 | 46th |
Industry Biological Products, Except Diagnostic Substances | 131 out of 236 | 45th |
Source: SEC filing on March 30, 2017.
Aberman's colleagues
We found one more compensation record of an executive who worked with Zami Aberman at Pluristem Therapeutics in 2014.
2014
Yaky Yanay
Pluristem Therapeutics
Chief Executive Officer
News
Pluristem Therapeutics CEO Yaky Yanay's 2022 pay falls 86% to $1.3M
February 27, 2023
Pluristem Therapeutics Chairman Zami Aberman's 2020 pay falls 54% to $501K
April 8, 2021
Pluristem Therapeutics Chairman Zami Aberman's 2019 pay jumps 85% to $1.1M
May 20, 2020
Pluristem Therapeutics CEO Zami Aberman's 2018 pay falls 83% to $593K
April 25, 2019